Heated Chemotherapy (HITHOC and HIPEC)

Heated Chemotherapy Profile
HITHOC (Pleural) & HIPEC (Peritoneal)
Category	Treatment
Temperature Range	40–43°C
Primary Agent	Cisplatin
HITHOC Survival	20.5 months (median)
HIPEC Survival	53 months (median)
HIPEC 5-Year OS	47%
Perfusion Duration	60–120 minutes
30-Day Mortality	2–4%
Free Case Review →

Heated Chemotherapy for Mesothelioma: How HITHOC and HIPEC Improve Survival by Up to 127 Months

Executive Summary

Heated chemotherapy represents one of the most significant advances in mesothelioma treatment, combining cytoreductive surgery with high-concentration chemotherapy solutions heated to 40–43°C and circulated directly within the body cavity where the tumor originated. Two distinct procedures have emerged for the two primary forms of mesothelioma: Hyperthermic Intrathoracic Chemotherapy (HITHOC) for pleural mesothelioma and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal mesothelioma.

The scientific rationale is compelling: hyperthermia selectively destroys cancer cells at temperatures that normal tissue can tolerate, while simultaneously increasing drug penetration from approximately 1–2 mm to up to 5 mm into tumor tissue. For pleural mesothelioma, a National Cancer Database analysis of 3,232 patients found HITHOC independently improved overall survival (HR 0.80, p=0.002), with a median of 20.5 months versus 16.8 months without HITHOC. For peritoneal mesothelioma, CRS-HIPEC has transformed outcomes from a median survival of under 12 months to 53 months in the landmark multi-institutional registry, with 5-year survival rates reaching 47%.

At experienced high-volume centers, 30-day mortality for both HITHOC and HIPEC ranges from 2% to 4%, and patients achieving complete cytoreduction with HIPEC have achieved median survival exceeding 10 years. The completeness of tumor removal and histologic subtype remain the most powerful predictors of outcome for both procedures.

Key Facts

Key Facts: Heated Chemotherapy for Mesothelioma

Two procedures: HITHOC targets pleural mesothelioma; HIPEC targets peritoneal mesothelioma Temperature range: 40–43°C — cancer cells die at these temperatures while normal cells survive up to 45°C Drug penetration: Heat increases chemotherapy tissue penetration from 1–2 mm to up to 5 mm Primary agent: Cisplatin is the most commonly used chemotherapy drug in both HITHOC and HIPEC HITHOC survival benefit: 20.5 months vs. 16.8 months median OS in NCDB study of 3,232 patients (HR 0.80) HIPEC landmark data: 53-month median survival and 47% 5-year survival in 405-patient multi-institutional registry Best HIPEC outcomes: Complete cytoreduction (CC-0) achieves 94-month median survival; CC-0/1 with cisplatin at Wake Forest: 127 months Largest HITHOC study: German multicenter registry of 350 patients across 4 university centers Mortality rates: 2–4% at high-volume centers for both procedures Patient selection: Epithelioid histology, good performance status (ECOG 0–1), and achievable complete resection are required Immunotherapy synergy: Preclinical 2024 data shows HITHOC enhances T-cell infiltration and response to checkpoint inhibitors Perfusion duration: HITHOC typically 60–90 minutes; HIPEC typically 90–120 minutes

What Is the Scientific Basis for Heated Chemotherapy?

The combination of hyperthermia and cytotoxic drugs produces cancer cell killing that exceeds what either treatment achieves alone. This synergism operates through multiple mechanisms that researchers have identified over decades of laboratory and clinical investigation.

Hyperthermia disrupts tumor cell membranes, increasing their permeability and allowing chemotherapy agents to penetrate deeper into tissue. At normothermic temperatures (37°C), cisplatin penetrates approximately 1–2 mm into tumor deposits, but at hyperthermic temperatures (42°C), penetration increases to approximately 5 mm. This enhanced drug uptake is critical because mesothelioma typically grows as a diffuse sheet across serosal surfaces rather than as discrete nodules.

Cancer cells are selectively vulnerable to heat in the 41–43°C range due to increased lysosomal enzyme activity specific to malignant cells. Normal cells tolerate temperatures up to approximately 45°C, creating a therapeutic window. Hyperthermia also depresses oxidative metabolism in tumor cells, causing accumulation of lactic acid and decreased pH in the tumor microenvironment, which further accelerates cell death. Additionally, heat reduces chemoresistance — a major clinical problem in mesothelioma — by amplifying the cytotoxic effect of cisplatin even at temperatures below 42°C.

"The highest thermal enhancement ratios have been observed for alkylating agents such as cisplatin, melphalan, and cyclophosphamide — the very drugs most commonly used in intraoperative perfusion protocols for mesothelioma."

— David Foster, Patient Advocate, Danziger & De Llano

How Does HITHOC Work for Pleural Mesothelioma?

HITHOC is performed immediately following cytoreductive surgery for pleural mesothelioma, most commonly pleurectomy/decortication (P/D). After the surgeon removes all visible tumor from the chest cavity, a heated chemotherapy solution is circulated through the thoracic space using a closed-circuit perfusion system. The goal is to destroy microscopic residual cancer cells that surgery alone cannot remove.

In the German multicenter study — the largest HITHOC dataset worldwide — 350 patients were treated across four university centers (Regensburg, Munich, Heidelberg, Freiburg) from 2008 to 2019. Extended P/D was the most common surgical approach (75% of cases), followed by standard P/D (22%) and EPP (3%). Macroscopic complete resection was achieved in 86% of patients. Additional structures resected included the diaphragm (65.7%), pericardium (44.6%), and chest wall (10%).

Dosing Protocols

Cisplatin is the primary chemotherapy agent used in HITHOC, administered either alone or combined with doxorubicin:

Regimen	Patients	Dosing
Cisplatin alone	61%	Median 108.8 mg/m² (range 51–200 mg/m²)
Cisplatin + doxorubicin	39%	Cisplatin 108.8 mg/m² + doxorubicin 46.9 mg/m²
Low-dose cisplatin (≤125 mg/m²)	67%	Reduced nephrotoxicity risk
High-dose cisplatin (>125 mg/m²)	33%	2.7× higher renal insufficiency risk (p=0.006)

Perfusion is typically performed for 60–90 minutes at a maximum temperature of 42°C with a perfusion volume of approximately 5,000 mL. An Egyptian comparative trial used cisplatin at 125 mg/m² infused for 70 minutes at 40–43°C.

Survival Outcomes

Multiple studies have demonstrated a survival advantage for HITHOC when added to cytoreductive surgery:

Study	Patients	With HITHOC	Without HITHOC	Significance
NCDB propensity-matched (2023)	3,232 (365 HITHOC)	20.5 months	16.8 months	HR 0.80, p=0.002
Systematic review (2025)	7 studies	13–35 months	11–22.8 months	6 of 7 studies showed benefit
Randomized pilot (2021)	27	28 months	19 months	HR 0.77
Epithelioid subgroup (pilot)	subset	45 months	15 months	3× survival advantage

The largest analysis — a propensity-score matched study using the National Cancer Database — demonstrated that HITHOC was independently associated with improved overall survival and, notably, decreased 30-day mortality (3.2% vs. 6.0%, p=0.017) despite increased length of stay (12 vs. 7 days).

Immunomodulatory Effects

Preclinical research published in 2024 demonstrated that HITHOC remodels the tumor immune microenvironment by promoting T-cell infiltration and enhancing immune checkpoint expression. In murine models, HITHOC synergized with dual PD-1 and CTLA-4 inhibition, providing a scientific rationale for combining HITHOC with immunotherapy in future clinical trials.

How Does HIPEC Work for Peritoneal Mesothelioma?

CRS-HIPEC has transformed peritoneal mesothelioma from a rapidly fatal disease with median survival of 6–16 months into one where long-term survival exceeding 10 years is achievable in selected patients. The procedure involves maximal cytoreductive surgery to remove all visible tumor deposits from the peritoneal surfaces, followed by perfusion of the abdominal cavity with heated chemotherapy.

The Peritoneal Cancer Index

The Peritoneal Cancer Index (PCI), developed by Sugarbaker, is the standard method for quantifying peritoneal disease burden before and during surgery. The abdomen is divided into 13 regions — 9 abdominal regions (numbered 0–8 in clockwise fashion) plus 4 small bowel segments (upper/lower jejunum, upper/lower ileum). Each region receives a Lesion Size score from 0 (no tumor) to 3 (>5 cm or confluence), producing a total PCI score from 0 to 39.

PCI profoundly impacts prognosis: patients with PCI ≤20 achieved a median overall survival of 119 months, compared to only 39 months when PCI exceeded 20. At Wake Forest Baptist Medical Center — one of the world's highest-volume centers with 28 years of experience and 111 peritoneal mesothelioma patients — the mean PCI at first CRS-HIPEC was 18.7.

Completeness of Cytoreduction

The completeness of cytoreduction (CC) score is the single most powerful predictor of survival after CRS-HIPEC:

CC Score	Residual Disease	Median Survival
CC-0	No visible disease	94 months
CC-1	Nodules <2.5 mm	67 months
CC-2	Nodules 2.5 mm–2.5 cm	40 months
CC-3	>2.5 cm or confluence	12 months

CC-0 and CC-1 are considered complete cytoreductions because residual nodules ≤2.5 mm are thought to be penetrable by the heated intraperitoneal chemotherapy. At Wake Forest, patients achieving R0-R1 complete cytoreduction had a median overall survival of 127 months — more than 10 years — versus only 3.0 months for R2c (incomplete) resections.

HIPEC Agents and Protocols

Agent	Dosing	Duration	Notes
Cisplatin	200–250 mg/m²	90 min	Currently preferred first-line agent
Cisplatin + doxorubicin	50–100 + 15–45 mg/m²	90 min	Better OS (HR 0.54) in RENAPE study
Mitomycin C	30–40 mg/m²	90–120 min	Earlier standard; inferior to cisplatin
Carboplatin	500–1,000 mg/m²	90 min	Occasional alternative

The Wake Forest group demonstrated that switching from mitomycin C to cisplatin significantly improved outcomes: median OS of 42.4 months with cisplatin versus 11.6 months with mitomycin C (p=0.007). The RENAPE multicenter study (249 patients, 20 centers) showed that dual-agent HIPEC regimens achieved significantly better overall survival than single-agent regimens (HR 0.54, 95% CI 0.31–0.95) without increased major morbidity.

Survival Data from Major Centers

Center/Registry	Patients	Median OS	5-Year OS
Multi-institutional (8 centers, Yan et al.)	405	53 months	47%
Wake Forest Baptist	111	39 months	~40%
3 US institutions (Alexander et al.)	211	38.4 months	41%
India tertiary center	15	27 months	33% (3-year)
Meta-analysis (20 studies)	1,047	19–92 months	42%

The multi-institutional registry by Yan et al. (2009), published in the Journal of Clinical Oncology and encompassing 405 patients from eight centers worldwide, remains the landmark dataset. Epithelioid subtype, absence of lymph node metastasis, CC-0/CC-1 resection, and HIPEC itself were all independently associated with improved survival.

Who Is a Candidate for Heated Chemotherapy?

Patient selection is critical for both HITHOC and HIPEC, and treatment decisions should be made at specialized high-volume centers with multidisciplinary expertise.

HITHOC Candidacy (Pleural Mesothelioma)

• Performance status: ECOG 0–1 (95% of German HITOC cohort); Karnofsky index ≥80% (83% of cohort)
• Histology: Epithelioid strongly preferred (85% of German cohort); biphasic considered selectively; sarcomatoid generally excluded
• Disease stage: UICC stages I–III (98% of German cohort); stage IV only rarely considered
• Surgical goal: Macroscopic complete resection must be achievable — HITHOC targets only microscopic residual disease
• No distant metastases: Extra-thoracic spread is a contraindication
• Age: Mean age 61.5 years in the German study; no strict cutoff but older patients require careful evaluation

HIPEC Candidacy (Peritoneal Mesothelioma)

• Performance status: ECOG 0–1 preferred; ECOG 2 considered cautiously; ECOG 3 associated with 13× higher mortality hazard
• Histology: Epithelioid offers best outcomes (38–51 months median OS); biphasic may benefit if CC-0 achievable; sarcomatoid is a contraindication at most centers
• PCI score: Lower PCI (≤20) strongly preferred — associated with 119-month vs. 39-month median survival
• Complete resection: CC-0/CC-1 must be achievable; if only CC-2 or CC-3 expected, CRS-HIPEC is generally not performed with curative intent
• No extra-abdominal metastases or positive lymph nodes
• Age: Age <60 independently associated with favorable outcomes; average age 55 years at Wake Forest

Contraindications

Heated chemotherapy is generally contraindicated in patients with sarcomatoid histologic subtype, extra-cavitary metastases, poor performance status (ECOG >2), inability to achieve macroscopic complete resection, or significant comorbidities precluding major surgery. For HIPEC specifically, extensive small bowel mesenteric involvement that prohibits adequate cytoreduction is an absolute contraindication. Patients with initially unresectable disease may be referred for neoadjuvant systemic chemotherapy to potentially downstage the tumor before reconsidering surgery.

What Are the Complications and Risks?

Renal Toxicity

Cisplatin-induced nephrotoxicity is the most feared complication specific to heated chemotherapy. In the German HITHOC multicenter study, 12% of patients developed renal insufficiency overall, though only 1.4% required temporary dialysis. High-dose cisplatin (>125 mg/m²) increased the risk 2.7-fold (p=0.006) and was associated with a 12.2-fold higher likelihood of in-hospital mortality (p=0.001). For HIPEC, reported nephrotoxicity rates with cisplatin range from 3.7% to 36%, depending on dosing and renal protection protocols. Sodium thiosulfate, amifostine, and perioperative fluid balancing are used for renal protection, though no standardized protocol exists.

Surgical Complications

For HITHOC, the German multicenter study reported an overall complication rate of 51%, with surgical revision required in 15% of patients for air leaks, hemothorax, chylothorax, or empyema. Pneumonia occurred in 15%, prolonged air leak (>7 days) in 11%, new atrial fibrillation in 12%, and respiratory insufficiency in 10%. The median ICU stay was 2 days and median hospital stay was 18 days.

For HIPEC, the multi-institutional Yan et al. registry reported an overall complication rate of 46%, with 31% classified as grade 3–4 (severe). A meta-analysis of 20 studies found morbidity rates ranging from 8% to 90%, largely reflecting differences in institutional experience and learning curves.

Mortality Rates

Setting	30-Day/In-Hospital Mortality
HITHOC (German multicenter, n=350)	3.7%
HITHOC (NCDB, n=365)	3.2%
HIPEC (Wake Forest, n=111 MPM)	2.7%
HIPEC (8-center registry, n=405)	2.0%
HIPEC (3 US centers, n=211)	2.3%

A 2025 systematic review found no reported mortality directly attributable to HITHOC-specific complications across all seven included studies. Deaths were attributed to surgical complications or pre-existing comorbidities rather than the heated perfusion itself.

What Clinical Trials Are Investigating Heated Chemotherapy?

Active HITHOC Trials

An active registered trial (NCT05508555) is comparing pleurectomy/decortication with versus without HITHOC using cisplatin at 125 mg/m² infused for 70 minutes at 40–43°C for localized malignant pleural mesothelioma. The 2024 preclinical data demonstrating HITHOC synergy with dual PD-1/CTLA-4 blockade provides strong rationale for clinical combination trials with immunotherapy, which are anticipated.

Active HIPEC Trials

Several HIPEC-related trials are ongoing or recently reported. An individualized HIPEC response assessment study is evaluating ex vivo mass response testing to personalize HIPEC agent selection for peritoneal carcinomatosis including mesothelioma. The INTERACT MESO phase I/II trial is investigating intraperitoneal paclitaxel for primary malignant peritoneal mesothelioma. A phase II trial (NTR7060) at Erasmus MC is evaluating adjuvant dendritic cell-based immunotherapy after CRS-HIPEC, with early results showing feasibility and T-cell memory activation. Novel approaches including PIPAC (pressurized intraperitoneal aerosol chemotherapy) are being studied as potential neoadjuvant strategies to downstage initially unresectable peritoneal mesothelioma.

How Does Heated Chemotherapy Connect to Mesothelioma Compensation?

Patients diagnosed with mesothelioma who undergo HITHOC or HIPEC may be eligible for significant compensation through multiple pathways. The cost of these specialized procedures — which require treatment at experienced high-volume centers — combined with travel, extended hospital stays, and lost income creates substantial financial burden for patients and families.

More than 60 active asbestos trust funds hold over $30 billion for mesothelioma victims, and patients can file claims with multiple trusts simultaneously. Mesothelioma lawsuits have produced some of the largest verdicts in personal injury law. An experienced mesothelioma attorney can help patients navigate the claims process while they focus on treatment and recovery. Veterans with service-connected asbestos exposure may also qualify for VA disability benefits and healthcare coverage.

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Related Resources

• Pleurectomy and Decortication
• Immunotherapy for Mesothelioma
• Mesothelioma Treatment Options
• Mesothelioma Clinical Trials
• Mesothelioma Treatment Centers
• Mesothelioma Diagnosis and Staging

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice